Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/1998

01-06-1998

Estrogen receptor negative and progesterone receptor positive primary breast cancer: Pathological characteristics and clinical outcome

Authors: Agnès Bernoux, Patricia de Cremoux, Christine Lainé-Bidron, Emmanuel C. Martin, Bernard Asselain, Henri Magdelénat

Published in: Breast Cancer Research and Treatment | Issue 3/1998

Login to get access
Metadata
Title
Estrogen receptor negative and progesterone receptor positive primary breast cancer: Pathological characteristics and clinical outcome
Authors
Agnès Bernoux
Patricia de Cremoux
Christine Lainé-Bidron
Emmanuel C. Martin
Bernard Asselain
Henri Magdelénat
Publication date
01-06-1998
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/1998
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1006011328655

Other articles of this Issue 3/1998

Breast Cancer Research and Treatment 3/1998 Go to the issue

Legacy

Author Index, Subject Index

OriginalPaper

Fibrotic focus in infiltrating ductal carcinoma of the breast: A significant histopathological prognostic parameter for predicting the long-term survival of the patients

OriginalPaper

Fractal analysis of mammographic lesions: A prospective, blinded trial

OriginalPaper

High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancers

OriginalPaper

Western diet, early puberty, and breast cancer risk

OriginalPaper

Modulation of estrogen receptor gene expression in human breast cancer cells: A decoy strategy with specific PCR-generated DNA fragments
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits